Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with h...
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
About this item
Full title
Author / Creator
Dent, Rebecca , Cortés, Javier , Park, Yeon Hee , Muñoz-Couselo, Eva , Kim, Sung-Bae , Sohn, Joohyuk , Im, Seock-Ah , Holgado, Esther , Foukakis, Theodoros , Kümmel, Sherko , Yearley, Jennifer , Wang, Anran , Nebozhyn, Michael , Huang, Lingkang , Cristescu, Razvan , Jelinic, Petar , Karantza, Vassiliki and Schmid, Peter
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the tumor microenvironment that might be predictive of response.
Cell fractions from 20 paired samples collected at b...
Alternative Titles
Full title
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4b4962b9db324675a0d0e9eac3dbd9f3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4b4962b9db324675a0d0e9eac3dbd9f3
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-024-01946-y
